HCA Q2 2026: Payer-Mix Shift Hits EBITDA, Florida Medicaid Boosts, $7B Capex Unveiled

Transcript intelligence

What changed

HCA beat EPS by a narrow 0.4% ($7.59 vs $7.56 estimate) and revenue by 2.4% ($20.23B vs $19.76B estimate). The most significant change from the prior quarter is the shift in guidance sentiment from maintained to lowered. Revised 2026 targets call for revenue of $77-79.5B and adjusted EBITDA of $15.4-16.1B, reflecting the $400M EBITDA impact from the exchange payer-mix shift. A $540M net benefit from the newly approved Florida Medicaid supplemental payment program was booked in Q2, a major new positive versus the prior quarter when Florida approval was still pending. The patient migration rate from exchanges to uninsured was nearly 1-for-1, worse than the previously assumed 80-85% rate. On the capital side, management unveiled a $7B three-year capex plan, an increase from the prior quarter's $5.5-6B approved project pipeline. Elective surgery volumes declined 6% year-over-year, while ER, cardiac, and rehab volumes remained strong. The bullish score declined from 70 to 65.

Guidance delta

Guidance was lowered from the prior quarter's maintained stance. 2026 revenue is now targeted at $77-79.5B and adjusted EBITDA at $15.4-16.1B, reflecting the approximately $400M EBITDA headwind from the exchange payer-mix shift. In Q1 2026, management had maintained guidance with 2-3% volume growth expectations. Management characterized the revised targets as aligned with long-term adjusted EBITDA growth expectations of 4-6%. The capex outlook increased, with $7B planned over three years versus the prior quarter's $5.5-6B approved project pipeline.

Key takeaways

• HCA beat EPS ($7.59 vs $7.56) and revenue ($20.23B vs $19.76B), but the beat was accompanied by a lowered full-year outlook.
• The expiration of enhanced premium tax credits drove a near 1-for-1 migration of exchange patients to uninsured status, causing an approximately $400M adjusted EBITDA headwind.
• The newly approved Florida Medicaid supplemental program added $540M in net benefit in Q2, partially offsetting the payer-mix deterioration.
• Management announced $7B in capex over three years to add 1,000-1,200 inpatient beds and 250-300 outpatient facilities, signaling continued capacity expansion.
• Elective surgeries declined 6% YoY, but ER, cardiac, and rehab volumes supported overall volume growth.
• The financial resiliency program is delivering cost improvements, with same-facility cost per admission flat to slightly up year-over-year.

Management priorities

• Deploy $7B of capex over three years to expand inpatient and outpatient capacity in high-growth markets.
• Continue the financial resiliency program focused on digital transformation and shared-service efficiencies.
• Monitor and adapt to Medicaid work-requirement regulations and other policy changes including OPPS and IDR reforms.
• Maintain share repurchases and dividends while leveraging a strong balance sheet.
• Pursue additional Medicaid supplemental program approvals beyond the newly approved Florida program.